Follicum announce today that the synthesis of the peptide has been completed. The peptide is the active ingredient of the product planned to be used in the clinical Phase I/IIa study. Production of product for the clinical Phase I/IIa study Follicum announced in early June that the company had signed an agreement with the peptide […]
Follicum’s half-year report 2015 (1 January to 30 June) is now published. Click here to open the report (in Swedish).
Follicum can today announce that an agreement has been signed with PolyPeptide Group and Recipharm AB prior to the clinical study, which is expected to start around the turn of the year 2015/2016. Read more here.